Dasatinib is a potent, oral, small-molecule multikinase inhibitor (API) used to treat Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Primarily, it acts as a BCR-ABL and SRC family inhibitor, often used for cases resistant to imatinib. It is available as a white to off-white solid in anhydrous (CAS 302962-49-8) and monohydrate (CAS 863127-77-9) forms, with a typical purity of $\ge$99%.